Humana, Inc. Stock Plummets to New 52-Week Low at $163.11

Humana, Inc., a mid-cap player in the healthcare services industry, has recently reached a new 52-week low of USD 163.11 on March 20, 2026. This significant decline reflects a challenging year for the company, with its stock price plummeting by 51.37% over the past year, contrasting sharply with the S&P 500's performance of 14.9% during the same period. Despite the downturn, Humana maintains a market capitalization of USD 32,327 million and a price-to-earnings (P/E) ratio of 27.00. The company has reported a return on equity (ROE) of 6.81%, which is below the industry average, indicating potential concerns regarding profitability. Additionally, Humana's price-to-book ratio stands at 1.83, suggesting that the stock may be trading at a premium compared to its book value. The company has also declared a dividend yield of 1.26%, although its financial metrics indicate a mixed performance. With a history of underperformance against the S&P 500 over the last three years, Humana's recent price movement underscores the ongoing challenges it faces in the competitive healthcare landscape.